PavesiLab

Tumor microenvironment, immunotherapy, and organ-on-a-chip technologies

[LKCMedicine Research @lkcmedresearch]

LKCMedicine's Cancer Discovery & Regenerative Medicine Programme faculty Asst Prof Andrea Pavesi together with colleagues used a ‘library’ of CAR T-cell designs to discover a next-generation treatment aimed at IL-13Rα2, a protein often found on glioblastoma cells. By screening this library in both lab-grown ‘mini-brain tumors’ and animal models, they identified a chimeric receptor that displayed strong tumor-killing abilities and long-term persistence. These results open the door to more effective, tailored CAR T-cell therapies for aggressive brain cancers. Read more in this link: https://t.co/4CIZqoCNFG

[LKCMedicine Research @lkcmedresearch]

LKCMedicine Asst Profs Andrea Pavesi and Giulia Adriani, both engineered a miniature, in vitro, liver-tumor model, where blood vessels form naturally from human cells. By mimicking the tumor environment, this system allows us to test how chemotherapy and T-cell immunotherapy affect solid tumors. This work include contributions from the LKCMedicine's Cancer Discovery & Regenerative Medicine Programme, shed light on how tumor vasculature influences drug delivery and immune-cell infiltration, paving the way for more effective treatments. Read more in the link here: https://t.co/MoBZbcgOiz

[Nature Rev Immunol @NatRevImmunol]

The OrganiX microfluidic system to recreate the complex tumour microenvironment https://t.co/8Ywb3PMiuz

[PavesiLab @PavesiLab]

Congratulations @ragavijayakumar for clinching the best poster award titled “Development of a Humanized Microphysiological Vascularized Immunocompetent Solid Tumour Model” during her presentation today! All the best for your PhD! You have got what it takes!

[PavesiLab @PavesiLab]

We live in an exciting era with endless possibilities using our platform.
Thank you @medical_xpress for the feature!
Discovery in T-cell research could lead to improved treatment of solid tumors https://t.co/FEFc7M8ZQQ
#oncology #immunotherapy #G9a #aimbiotech

[AIM Biotech @AIMBiotech]

Combine the power of @NikonInst's confocal microscopes with the detail of @AIMBiotech's blood-brain barrier (BBB) model: this stunning image comes from a new application note about imaging the BBB in vitro using idenTx #organonachip models. Take a look: https://t.co/cF0F1hq6yl

[ACIR @ACIR_org]

SPOTLIGHT: @astar_research researchers demonstrated that transient treatment with the small molecule inhibitor (UNC0642) of the epigenetic regulator G9a/GLP during ex vivo expansion of T cells improved the cytotoxic capability of [...] https://t.co/hjqHTbOxOZ

[PavesiLab @PavesiLab]

Great to see our work highlighted by ACIR in their newsletter @ACIR_org https://t.co/9egCPTl7hF

[SgSI @SgSI_Immunology]

This new study from @PavesiLab @GuccioneLab @bertoletti_lab and many more from Singapore, shows that G9a/GLP inhibitors increase the cytotoxicity of TCR-engineered T cells.

[Bertoletti Lab @bertoletti_lab]

Congrats @PavesiLab 👏
Very nice collaborative study showing that G9a/GLP inhibition is an effective method of improving the cytotoxicity of transiently engineered TCR-T cells, CAR-T cells and NK cells, via increase of granzyme secretion 👉https://t.co/yTiidG0jzZ

[PavesiLab @PavesiLab]

We identified an exciting way to enhance cell therapy. Check out our latest publication in Nature Comm to find out how we did it!
#celltherapy #imcb #astar #naturecomm

https://t.co/ohY6uMVKvO

[PavesiLab @PavesiLab]

Big news for organ chip technology and non-animal methods!

https://t.co/WVtm1lQvYO

[AIM Biotech @AIMBiotech]

Check out this article in @GENbio on our new organiX platform for #organoids and biopsies: as these types of samples are used more for #drugdiscovery and tumor characterization, creating perfusable vasculature in an immune-competent environment is vital. https://t.co/4nomLuDpRt

[PavesiLab @PavesiLab]

The Tissue Engineering and Regenerative Medicine International Society (TERMIS) – Asia-Pacific Conference 2022 is happening from they 5th to 8th October.

We are excited to have our very own Dr Maxine Lam present on the 8th October!

@2022termisap #tissueengineering

[PavesiLab @PavesiLab]

Jyothsna Vasudevan received a joint Ph.D. in Biomedical Engineering from SUTD and NUS. Her research focus was on understanding the influence of matrix stiffness on cancer cell migration decisions.

We’d like to welcome her into our team as our newest post doctoral fellow ☺️

[PavesiLab @PavesiLab]

Organ on a chip - a better and more reliable way to run drug tests! #microfluidics #CancerResearch

https://t.co/IlNI4epVbO

[AIM Biotech @AIMBiotech]

Researchers recently demonstrated the therapeutic potential of STING agonists in combination with NK cell-based #immunotherapy. @AIMBiotech's idenTx #drugdiscovery platform was instrumental in some of the key #research assays; check out the science here: https://t.co/lcoXFR1kzA

[PavesiLab @PavesiLab]

There is always a first time.
This time Nanostring hosted us on their new "spatial navigator podcast."
Check it out on Spotify, link below! https://t.co/dTpJyTXHDs

[PavesiLab @PavesiLab]

Our lab is looking to hire a postdoctoral fellow over at MBI! Interested applicants please submit your CV via LinkedIn! https://t.co/dkkmn16cQo

[PavesiLab @PavesiLab]

If you haven’t checked out our review article “In vitro 3D liver tumor microenvironment models for immune cell therapy optimization”, it is highlighted in APL Bioengineering email newsletter. Read it here: https://t.co/XNOQfN7W5m